A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers
A study published in January 2023 addresses the limited knowledge in the field of oncology regarding the use of moderate hyperthermia in cancer management. The review summarizes clinical data on the application of loco-regional and superficial hyperthermia as an adjunct to cancer treatment. It incorporates updated information from high-quality studies and meta-analyses. The methodology and results are presented in a summarized and tabulated format based on tumours type for easy reference.
Regional Hyperthermia therapy (RHT) involves applying moderate heat to tumours to enhance the effects of cancer treatments and improve responses. Despite its long history of use, the exact mechanisms of action are not fully understood. Challenges such as inconsistent practices, limited quality control, conflicting clinical evidence, and lack of familiarity have hindered its widespread adoption. However, several medical centres recognize its potential and have incorporated it into their standard treatment protocols. Recent advancements in technology have improved RHT, and a growing body of evidence has the potential to transform its use. This narrative review aims to summarize the findings of recently published prospective trials and evaluate the clinical effects of RHT when combined with standard cancer treatments. The review discusses 31 studies with higher-quality evidence across different tumours sites. Although not all of these studies are considered top-level evidence, they collectively demonstrate the benefits of moderate RHT in terms of improving local tumours control, survival outcomes, and quality of life scores across various cancer types, with minimal increase in side effects. This paper can serve as a valuable reference for considering the use of RHT in specific cases.
Read the full study HERE